A New NLRP3 Inflammasome Inhibitor, Dioscin, Promotes Osteogenesis

Small. 2020 Jan;16(1):e1905977. doi: 10.1002/smll.201905977. Epub 2019 Dec 9.

Abstract

Refractory periapical periodontitis, which is a persistent infection after root canal treatment, still has no effective treatment. Its most common pathogen is Enterococcus faecalis. Here, the precursor of phytosteroids, dioscin, is introduced to fight against the inflammation induced by Enterococcus faecalis. The findings suggest that dioscin inhibits the nuclear transport of NF-κB and the expression of reactive oxygen species (ROS) induced by lipoteichoic acid from the Enterococcus faecalis. The decrease in mRNA and protein levels of NLRP3, Caspase-1, and IL-1β is observed in dioscin treated mouse macrophages. In the MC3T3-E1 cells, dioscin also promotes the expression of osteogenic-related factors, ALP, Runx2, and OCN. The increased formation of mineralized nodules after the application of dioscin further indicates that dioscin has the potential to promote osteogenesis. The above results suggest dioscin can be a potential root canal irrigation or root canal sealant for the treatment of refractory apical periodontitis.

Keywords: ALP; NLRP3; OCN; bone resorption; dioscin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line
  • Diosgenin / analogs & derivatives*
  • Diosgenin / pharmacology
  • Humans
  • Lipopolysaccharides / pharmacology
  • Mice
  • NLR Family, Pyrin Domain-Containing 3 Protein / antagonists & inhibitors*
  • Osteogenesis / drug effects*
  • Teichoic Acids / pharmacology

Substances

  • Lipopolysaccharides
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • NLRP3 protein, human
  • Teichoic Acids
  • dioscin
  • lipoteichoic acid
  • Diosgenin